NSCLC
Conditions
Interventions
PD-L1 group:PD-L1 expression (IHC 22C3 pharmDx kit)
Sponsors
Beijing Cancer Hosptial
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to ensure that the samples qualifies for the study. 1. Patients must have a histologically confirmed primary NSCLC that is stage IIIB/IV, as classified by latest AJCC staging system, at the time of diagnosis. 2. Patients must be =18 years of age at diagnosis. 3. Patients must have a treatment-naive tumor tissue sample that was available for testing PD-L1, and from a site not previously irradiated. 4. Patients must have a formalin-fixed paraffin-embedded (FFPE) tumor tissue block available that is no older than 3 years. 5. Patients must have informed consent form (ICF) signed for any future study or have conditions that are accepted by IRB/ERC to waive ICF, OR are willing to sign the informed consent form.
Exclusion criteria
Exclusion criteria: All inclusion will be reviewed by the investigator or qualified designee to ensure that the samples qualifies for the study. No specific exclusion criteria was set for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PD-L1 express; | — |
Countries
China
Contacts
Public ContactTang Wenmin
Outcome results
None listed